NASDAQ · Biotechnology

Kinnate Biopharma Inc. (KNTE) Stock

$2.65 -0.38% NASDAQ: KNTE Healthcare

Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers.

Valuation

MetricValue
Price$2.65
Market Cap$124.99M
P/E Ratio-1.10
P/B Ratio0.77
P/S Ratio0.00
EPS (TTM)$-2.42
52-Week High$7.19
52-Week Low$1.04
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-58.86%
ROA-64.89%
ROCE-73.64%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio13.19

Annual Financials (USD)

Metric20192020202120222023
Revenue$0$0$0$0$0
Operating Profit$-12.0M$-36.0M$-90.0M$-119.0M$-119.0M
Net Profit$-12.0M$-35.0M$-89.0M$-114.0M$-113.0M
EPS$-0.28$-0.81$-2.05$-2.59$-2.42
Op Margin—————

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$78.0M$401.0M$367.0M$279.0M$174.0M
Total Liabilities$95.0M$7.0M$12.0M$20.0M$14.0M
Cash$76.0M$365.0M$116.0M$29.0M$57.0M
Borrowings$0$0$0$4.0M$3.0M

Latest News

The longer we live, the more we worry: AIA Longevity Study finds Singaporeans view longevity with more anxiety than opportunity PR Newswire · Jul 23, 2026 Dow Jones Futures: Google, Tesla Fall On Earnings, Capital Spending Investor's Business Daily · Jul 23, 2026 Australia jobs blow past expectations in June, cements bets of another rate rise Reuters · Jul 23, 2026 Bitwise CIO Names 2 Crypto Bets Best Positioned for the Next Bull Market BeInCrypto · Jul 23, 2026 MegazoneCloud and Korean Re Sign Strategic Agreement to Advance AX PR Newswire · Jul 23, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-11.0M$-30.0M$-71.0M$-89.0M$-100.0M
Investing Cash Flow$0$-32.0M$-181.0M$-10.0M$101.0M
Financing Cash Flow$80.0M$351.0M$36.0M$1.0M$-8.0M
Net Cash Flow$69.0M$289.0M$-215.0M$-95.0M$2.0M
Free Cash Flow$-11.0M$-30.0M$-72.0M$-92.0M$-100.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.16
EV / EBITDA-0.60
FCF Yield-80.04%
Quick Ratio13.19
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AADIAadi Bioscience, Inc. $2.05 -2.38% -1.49 $94.89M 0.00%
ATYR $0.49 +1.19% -0.72 $47.62M 0.00%
DBTXDecibel Therapeutics, Inc. $4.91 -0.81% -1.95 $123.37M 0.00%
GRAYGraybug Vision, Inc. $5.50 -10.80% -4.23 $120.98M 0.00%
NGMNGM Biopharmaceuticals, Inc. $1.54 -1.28% -0.89 $128.53M 0.00%

About Kinnate Biopharma Inc.

Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.

Kinnate Biopharma Inc. is headquartered in US.

Kinnate Biopharma Inc. (KNTE) stock trades at $2.65 with a market capitalization of $124.99M. The stock is valued at a price-to-earnings (P/E) ratio of -1.10, price-to-book of 0.77, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.04 and $7.19, and currently trades 63.1% below its 52-week high.

On profitability, Kinnate Biopharma Inc. generates a return on equity (ROE) of -58.86%, return on capital employed of -73.64%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.kinnate.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides